Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
The latest update is out from LENZ Therapeutics ( (LENZ) ).
LENZ Therapeutics, Inc. held its 2025 annual meeting of stockholders on June 10, 2025. During the meeting, shareholders elected Class III and Class I directors to serve until the 2027 and 2028 annual meetings, respectively. Additionally, the appointment of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025, was ratified.
The most recent analyst rating on (LENZ) stock is a Buy with a $37.00 price target. To see the full list of analyst forecasts on LENZ Therapeutics stock, see the LENZ Stock Forecast page.
Spark’s Take on LENZ Stock
According to Spark, TipRanks’ AI Analyst, LENZ is a Neutral.
LENZ Therapeutics is navigating significant financial challenges with ongoing losses and negative cash flows, underscoring the need for strategic improvement to achieve profitability. While the earnings call highlights positive regulatory and commercial developments, the stock is burdened by a weak valuation profile due to negative earnings. The technical analysis presents a neutral to slightly bearish outlook, which, combined with financial hurdles, results in a cautious overall score.
To see Spark’s full report on LENZ stock, click here.
More about LENZ Therapeutics
Average Trading Volume: 254,800
Technical Sentiment Signal: Buy
Current Market Cap: $899.6M
Find detailed analytics on LENZ stock on TipRanks’ Stock Analysis page.